How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study

Janus kinase 2 (JAK2) has been regarded as an essential target for the treatment of myeloproliferative neoplasms (MPNs). BBT594 and CHZ868, Type-II inhibitors of JAK2, illustrate satisfactory efficacy in preclinical MPNs and acute lymphoblastic leukemia (ALL) models. However, the L884P mutation of J...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Xiaotian, Sun, Huiyong, Pan, Peichen, Li, Dan, Zhu, Feng, Chang, Shan, Xu, Lei, Li, Youyong, Hou, Tingjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567357/
https://www.ncbi.nlm.nih.gov/pubmed/28831147
http://dx.doi.org/10.1038/s41598-017-09586-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567357/
https://www.ncbi.nlm.nih.gov/pubmed/28831147
http://dx.doi.org/10.1038/s41598-017-09586-3

Ejemplares similares